Improvement in Tardive Dyskinesia with Aripiprazole Use

Duggal HS . Aripiprazole-induced improvement in tardive dyskinesia. Can J Psychiatry 2003;48:771–2.

Kane JM Carson WH Saha AR McQuade RD Ingenito GG Zimbroff DL , and others. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and Schizoaffective disorder. J Clin Psychiatry 2002;63:763–71.

Toru M Miura S Kudo Y. Clinical experiences of OPC-14597, a dopamine autoreceptor agonist in schizophrenic patients. Neuropsychopharmacology 1994;10:122S.

Inoue A Miki S Seto M Kikuchi T Morita S Ueda H , and others. Aripiprazole, a novel antipsychotic drug, inhibits quinpirole-evoked GTPase activity but does not up-regulate dopamine D2 receptor following repeated treatment in the rat striatum. Eur J Pharmacol 1997;321:105–11.